193 related articles for article (PubMed ID: 30229993)
1. Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.
Suragh TA; Lewis P; Arana J; Mba-Jonas A; Li R; Stewart B; Shimabukuro TT; Cano M
Br J Clin Pharmacol; 2018 Dec; 84(12):2928-2932. PubMed ID: 30229993
[TBL] [Abstract][Full Text] [Related]
2. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
3. Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System.
Arana J; Mba-Jonas A; Jankosky C; Lewis P; Moro PL; Shimabukuro TT; Cano M
J Adolesc Health; 2017 Nov; 61(5):577-582. PubMed ID: 29061232
[TBL] [Abstract][Full Text] [Related]
4. Safety of the 9-Valent Human Papillomavirus Vaccine.
Shimabukuro TT; Su JR; Marquez PL; Mba-Jonas A; Arana JE; Cano MV
Pediatrics; 2019 Dec; 144(6):. PubMed ID: 31740500
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
[TBL] [Abstract][Full Text] [Related]
6. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.
Slade BA; Leidel L; Vellozzi C; Woo EJ; Hua W; Sutherland A; Izurieta HS; Ball R; Miller N; Braun MM; Markowitz LE; Iskander J
JAMA; 2009 Aug; 302(7):750-7. PubMed ID: 19690307
[TBL] [Abstract][Full Text] [Related]
7. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
[TBL] [Abstract][Full Text] [Related]
8. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
9. Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States.
Sonawane K; Lin YY; Damgacioglu H; Zhu Y; Fernandez ME; Montealegre JR; Cazaban CG; Li R; Lairson DR; Lin Y; Giuliano AR; Deshmukh AA
JAMA Netw Open; 2021 Sep; 4(9):e2124502. PubMed ID: 34533574
[TBL] [Abstract][Full Text] [Related]
10. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
11. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017.
Landazabal CS; Moro PL; Lewis P; Omer SB
Vaccine; 2019 Feb; 37(9):1229-1234. PubMed ID: 30660400
[TBL] [Abstract][Full Text] [Related]
12. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017.
Bonaldo G; Vaccheri A; D'Annibali O; Motola D
Br J Clin Pharmacol; 2019 Mar; 85(3):634-643. PubMed ID: 30569481
[TBL] [Abstract][Full Text] [Related]
14. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
Martin D; Menschik D; Bryant-Genevier M; Ball R
Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
Moro PL; Woo EJ; Marquez P; Cano M
Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
[TBL] [Abstract][Full Text] [Related]
16. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
[TBL] [Abstract][Full Text] [Related]
17. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
18. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
[TBL] [Abstract][Full Text] [Related]
20. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
